4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly EBT Margin came in at 3114.9% in Q1 2026, up 35002081.0% year-on-year from N/an in Q1 2025, and down 14809.3% on a QoQ basis from 21.18% in Q4 2025.
4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of EBT Margin data on file, last reported at 3114.9% in Q1 2026.
- On a quarterly basis, EBT Margin rose 35002081.0% year-over-year to 3114.9% in Q1 2026; TTM through Mar 2026 was 286.32%, a 97098759.0% increase from a year earlier, with the FY2025 full-year figure at 350.46%, up 78039278.0% from the prior year.
- EBT Margin for Q1 2026 stood at 3114.9%, down from 21.18% in the prior quarter.
- Over the last five years, EBT Margin for FDMT reached as high as 174063.16% in Q4 2023 and fell as low as 5055000.0% in Q4 2024.
- Historically, EBT Margin has averaged 567804.6% across 5 years, with a median of 21127.78% in 2022.
- Across the five-year window, EBT Margin tumbled 522906316 bps in 2024 and soared 505502118 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 2428.39% in 2022, then soared by 7268 bps to 174063.16% in 2023, then plunged by 3004 bps to 5055000.0% in 2024, then surged by 100 bps to 21.18% in 2025, then sank by 14809 bps to 3114.9% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 3114.9% in Q1 2026, 21.18% in Q4 2025, and 95417.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | -3,114.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,114.90% |
| Dec 31, 2025 | 21.18% |
| Sep 30, 2025 | -95,417.78% |
| Jun 30, 2025 | -599,246.67% |
| Mar 31, 2025 | -353,135.71% |
| Dec 31, 2024 | -5,055,000.00% |
| Sep 30, 2024 | -2,598,466.67% |
| Jun 30, 2024 | -909,000.00% |
| Mar 31, 2024 | -139,503.57% |
| Dec 31, 2023 | 174,063.16% |
| Sep 30, 2023 | -143.95% |
| Jun 30, 2023 | -21,454.39% |
| Mar 31, 2023 | -16,541.28% |
| Dec 31, 2022 | -2,428.39% |
| Sep 30, 2022 | -9,463.80% |
| Jun 30, 2022 | -21,127.78% |
| Mar 31, 2022 | -2,717.72% |
| Dec 31, 2021 | -28,560.87% |
| Sep 30, 2021 | -3,479.65% |
| Jun 30, 2021 | -74.03% |